2 Notes on the scope of the guidance

2 Notes on the scope of the guidance

NICE guidelines are developed in accordance with a scope that defines what the guideline will and will not cover. The scope of this guideline is available.

This guideline is relevant to people with Alzheimer's disease, vascular dementia, DLB, dementia with Parkinson's disease, subcortical dementia, frontotemporal dementias, and mixed cortical and subcortical dementia, as well as their families or carers, and all health and social care staff involved in the help, treatment and care of people with dementia and their families and carers including:

  • health and social care staff who have direct contact with people with dementia in hospital, community, home‑based, group‑care, residential or specialist‑care settings

  • health and social care staff working in the NHS, integrated health and social care services, statutory social services, and the voluntary and independent sectors.

The guideline does not specifically address:

  • the treatment and management of Creutzfeldt–Jakob disease

  • the physical treatments of organic disease sometimes associated with different forms of dementia, such as the treatment of convulsions or motor disorders

  • the treatment of physical ill health commonly encountered in elderly people, especially those with dementia, such as cardiovascular and neurological disorders, except where the treatment of such conditions may alter the progress of dementia.

How this guideline was developed

NICE commissioned the National Collaborating Centre for Mental Health, in partnership with the Social Care Institute for Excellence (SCIE), to develop this guideline. The Centre, with SCIE, established a Guideline Development Group (see appendix A), which reviewed the evidence and developed the recommendations. An independent Guideline Review Panel oversaw the development of the guideline (see appendix B).

There is more information about how NICE clinical guidelines are developed on the NICE website. A booklet, 'How NICE clinical guidelines are developed: an overview for stakeholders, the public and the NHS' is available.